{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T08:24:10Z","timestamp":1787387050869,"version":"build-2736575974"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s12325-026-03651-y","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T09:00:57Z","timestamp":1781254857000},"page":"4138-4161","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Assessment of the MFSAF v4.0 and PROMIS Fatigue\u00a07a to Measure Outcomes in Myelofibrosis: Validation from a Non-interventional Mixed Methods Study"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0012-3951","authenticated-orcid":false,"given":"Amy","family":"Howerter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Doll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Stroupe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elektra J.","family":"Papadopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avijeet S.","family":"Chopra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavita","family":"Sail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Fitzgerald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chad","family":"Gwaltney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Mascarenhas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Mesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"issue":"6","key":"3651_CR1","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/ajh.23690","volume":"89","author":"G Titmarsh","year":"2014","unstructured":"Titmarsh G, Duncombe A, McMullin M, et al. How common are myeloproliferative neoplasms? A systematic review and meta-analysis. Am J Hematol. 2014;89(6):581\u20137.","journal-title":"Am J Hematol"},{"issue":"10","key":"3651_CR2","doi-asserted-by":"publisher","first-page":"e37","DOI":"10.1038\/bcj.2011.36","volume":"1","author":"F Cervantes","year":"2011","unstructured":"Cervantes F. How I treat splenomegaly in myelofibrosis. Blood Cancer J. 2011;1(10):e37-e.","journal-title":"Blood Cancer J"},{"issue":"13","key":"3651_CR3","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","volume":"113","author":"F Cervantes","year":"2009","unstructured":"Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113(13):2895\u2013901.","journal-title":"Blood"},{"key":"3651_CR4","first-page":"89","volume":"7","author":"T Mughal","year":"2014","unstructured":"Mughal T, Vaddi K, Sarlis N, Verstovsek S. Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes. Int J Gen Med. 2014;7:89\u2013101.","journal-title":"Int J Gen Med"},{"key":"3651_CR5","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.leukres.2017.05.012","volume":"59","author":"C Gwaltney","year":"2017","unstructured":"Gwaltney C, Paty J, Kwitkowski VE, et al. Development of a harmonized patient-reported outcome questionnaire to assess myelofibrosis symptoms in clinical trials. Leuk Res. 2017;59:26\u201331.","journal-title":"Leuk Res"},{"issue":"5 (Suppl 1)","key":"3651_CR6","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1097\/01.mlr.0000258615.42478.55","volume":"45","author":"D Cella","year":"2007","unstructured":"Cella D, Yount S, Rothrock N, et al. The Patient-Reported Outcomes Measurement Information System (PROMIS). Med Care. 2007;45(5 (Suppl 1)):S3\u201311.","journal-title":"Med Care"},{"issue":"5","key":"3651_CR7","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1002\/(SICI)1097-0142(19990301)85:5<1186::AID-CNCR24>3.0.CO;2-N","volume":"85","author":"TR Mendoza","year":"1999","unstructured":"Mendoza TR, Wang XS, Cleeland CS, et al. The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer. 1999;85(5):1186\u201396.","journal-title":"Cancer"},{"issue":"21","key":"3651_CR8","doi-asserted-by":"publisher","first-page":"4869","DOI":"10.1002\/cncr.26129","volume":"117","author":"RA Mesa","year":"2011","unstructured":"Mesa RA, Kantarjian H, Tefferi A, et al. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer. 2011;117(21):4869\u201377.","journal-title":"Cancer"},{"issue":"9","key":"3651_CR9","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799\u2013807.","journal-title":"N Engl J Med"},{"key":"3651_CR10","first-page":"2168","volume":"130","author":"AC Dueck","year":"2017","unstructured":"Dueck AC, Gwaltney C, Chen W-H, et al. Quantitative testing of the myelofibrosis symptom assessment form version 4.0, a harmonized patient-reported outcome measure for collecting key secondary endpoint data in myelofibrosis clinical trials. Blood. 2017;130:2168.","journal-title":"Blood"},{"issue":"16_suppl","key":"3651_CR11","doi-asserted-by":"publisher","first-page":"e23106","DOI":"10.1200\/JCO.2024.42.16_suppl.e23106","volume":"42","author":"A Cardellino","year":"2024","unstructured":"Cardellino A, Zhang S, Phiri K, Gelhorn H, Cutts K. Patient (pt) interview\u2013based content validation of the Myelofibrosis Symptom Assessment Form version 4.0 (MFSAF v4.0). J Clin Oncol. 2024;42(16_suppl):e23106-e.","journal-title":"J Clin Oncol"},{"issue":"10","key":"3651_CR12","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1016\/j.apmr.2010.08.033","volume":"92","author":"J-S Lai","year":"2011","unstructured":"Lai J-S, Cella D, Choi S, et al. How item banks and their application can influence measurement practice in rehabilitation medicine: a PROMIS fatigue item bank example. Arch Phys Med Rehabil. 2011;92(10):S20\u20137.","journal-title":"Arch Phys Med Rehabil"},{"key":"3651_CR13","doi-asserted-by":"crossref","unstructured":"Harrison CN, Gerds AT, Kiladjian J-J, et al. Pacifica: a randomized, controlled phase\u00a03 study of pacritinib vs Physician\u2019s choice in patients with primary myelofibrosis, post polycythemia vera myelofibrosis, or post essential thrombocytopenia myelofibrosis with severe thrombocytopenia (platelet count< 50,000\/mL). Blood. 2019;134:4175.","DOI":"10.1182\/blood-2019-129245"},{"issue":"10","key":"3651_CR14","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1200\/JCO.2012.44.4489","volume":"31","author":"RA Mesa","year":"2013","unstructured":"Mesa RA, Gotlib J, Gupta V, et al. Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2013;31(10):1285.","journal-title":"J Clin Oncol"},{"issue":"1","key":"3651_CR15","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s41687-019-0100-y","volume":"3","author":"H Staunton","year":"2019","unstructured":"Staunton H, Willgoss T, Nelsen L, et al. An overview of using qualitative techniques to explore and define estimates of clinically important change on clinical outcome assessments. J Patient Rep Outcomes. 2019;3(1):16.","journal-title":"J Patient Rep Outcomes"},{"key":"3651_CR16","unstructured":"United States Food & Drug Administration. Patient-focused drug development: selecting, developing, or modifying fit-for-purpose clinical outcome assessments 2025. https:\/\/www.fda.gov\/media\/159500\/download. Accessed Apr 15, 2024."},{"key":"3651_CR17","unstructured":"Northwestern University. HealthMeasures. http:\/\/healthmeasures.net. 2024. Accessed Apr 15, 2024."},{"key":"3651_CR18","volume-title":"SF-12v2\u2122: how to score version 2 of the SF-12\u00ae health survey","author":"JE Ware","year":"2002","unstructured":"Ware JE, Kosinski M, Turner-Bowker DM, Gandek B. SF-12v2\u2122: how to score version 2 of the SF-12\u00ae health survey. Science Open; 2002."},{"key":"3651_CR19","volume-title":"How to score version 2 of the SF-12\u00a0health survey (with a supplement documenting version 1)","author":"J Ware","year":"2002","unstructured":"Ware J. How to score version 2 of the SF-12\u00a0health survey (with a supplement documenting version 1). Health Assessment Lab; 2002."},{"issue":"9","key":"3651_CR20","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1016\/0959-8049(94)90182-1","volume":"30A","author":"RK Portenoy","year":"1994","unstructured":"Portenoy RK, Thaler HT, Kornblith AB, et al. The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer. 1994;30A(9):1326\u201336.","journal-title":"Eur J Cancer"},{"issue":"9","key":"3651_CR21","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/j.leukres.2009.01.035","volume":"33","author":"RA Mesa","year":"2009","unstructured":"Mesa RA, Schwager S, Radia D, et al. The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leuk Res. 2009;33(9):1199\u2013203.","journal-title":"Leuk Res"},{"issue":"2","key":"3651_CR22","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","volume":"3","author":"V Braun","year":"2006","unstructured":"Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3(2):77\u2013101.","journal-title":"Qual Res Psychol"},{"issue":"8","key":"3651_CR23","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.jval.2011.06.013","volume":"14","author":"DL Patrick","year":"2011","unstructured":"Patrick DL, Burke LB, Gwaltney CJ, et al. Content validity\u2014establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: Part 2\u2014assessing respondent understanding. Value Health. 2011;14(8):978\u201388.","journal-title":"Value Health"},{"issue":"1","key":"3651_CR24","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1177\/160940690600500107","volume":"5","author":"J Fereday","year":"2006","unstructured":"Fereday J, Muir-Cochrane E. Demonstrating rigor using thematic analysis: a hybrid approach of inductive and deductive coding and theme development. Int J Qual Methods. 2006;5(1):80\u201392.","journal-title":"Int J Qual Methods"},{"issue":"3","key":"3651_CR25","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/BF02310555","volume":"16","author":"LJ Cronbach","year":"1951","unstructured":"Cronbach LJ. Coefficient alpha and the internal structure of tests. Psychometrika. 1951;16(3):297\u2013334.","journal-title":"Psychometrika"},{"issue":"2","key":"3651_CR26","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1586\/erp.11.12","volume":"11","author":"LD McLeod","year":"2011","unstructured":"McLeod LD, Coon CD, Martin SA, Fehnel SE, Hays RD. Interpreting patient-reported outcome results: US FDA guidance and emerging methods. Expert Rev Pharmacoecon Outcomes Res. 2011;11(2):163\u20139.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"3651_CR27","volume-title":"Psychometric Theory","author":"J Nunnally","year":"1994","unstructured":"Nunnally J. The assessment of reliability. In: Psychometric Theory, 3rd edn. New York: McGraw Hill;1994."},{"issue":"1","key":"3651_CR28","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12955-019-1121-1","volume":"17","author":"R Mesa","year":"2019","unstructured":"Mesa R, Su Y, Woolfson A, et al. Development of a symptom assessment in patients with myelofibrosis: qualitative study findings. Health Qual Life Outcomes. 2019;17(1):61.","journal-title":"Health Qual Life Outcomes"},{"issue":"11","key":"3651_CR29","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000966","volume":"7","author":"R Mesa","year":"2023","unstructured":"Mesa R, Harrison C, Palmer J, et al. Patient-reported outcomes and quality of life in anemic and symptomatic patients with myelofibrosis: results from the MOMENTUM Study. Hemasphere. 2023;7(11):e966.","journal-title":"Hemasphere"},{"issue":"2","key":"3651_CR30","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/bjh.12375","volume":"162","author":"C Harrison","year":"2013","unstructured":"Harrison C, Mesa R, Kiladjian J, et al. Health-related quality of life and symptoms in myelofibrosis patients treated with ruxolitinib versus best available therapy. Br J Haematol. 2013;162(2):229\u201339.","journal-title":"Br J Haematol"},{"issue":"6","key":"3651_CR31","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1007\/s11136-018-1827-2","volume":"27","author":"F Palandri","year":"2018","unstructured":"Palandri F, Benevolo G, Iurlo A, et al. Life for patients with myelofibrosis: the physical, emotional and financial impact, collected using narrative medicine\u2014results from the Italian \u2018Back to Life\u2019 project. Qual Life Res. 2018;27(6):1545\u201354.","journal-title":"Qual Life Res"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03651-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03651-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03651-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T08:04:45Z","timestamp":1787385885000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03651-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["3651"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03651-y","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]},"assertion":[{"value":"7 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Elektra J Papadopoulos, Avijeet S Chopra, Kristina Fitzgerald, and Kavita Sail are employees of the funding company. Chad Gwaltney has received consulting fees from the funding company. Helen Doll, Amy Howerter, and Angela Stroupe have no relevant financial or non-financial interests to disclose. John Mascarenhas reports Research funding paid to my institution from Incyte, Abbvie, SOBI, Novartis, Geron, Kartos, Karyopharm, BMS, PharmaEssentia, DISC and consulting, advisory or DSMB fees from Incyte, Abbvie, SOBI, Novartis, Kartos, Geron, Karyopharm, GSK, BMS, Pfizer, Roche, Disc, PharmaEssentia, Italafarmacia, Keros amd Merck. Ruben Mesa reports Consultant (Honoraria) over past 3\u00a0years: Abbvie, Blueprint, BMS, CTI, Genentech, Geron, GSK, Incyte, Novartis, Sierra, Sierra Oncology, Telios and Research Support: Abbvie, Blueprint, BMS, CTI, Genentech, Incyte, Morphosys, Sierra.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study received ethics approval in the USA, Canada, and the UK.\u00a0This study was performed in accordance with the ethical standards of the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. All study documents were submitted and approved by Western Copernicus Group (IRB approval number 20204626). Participants confirmed their consent to participate and for their data to be included for study related publications.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}}]}}